TELA Bio to Participate in Canaccord Genuity Medical Technologies and Diagnostics Forum
MALVERN, Pa., Nov. 9, 2016 /PRNewswire/ -- TELA Bio, Inc., a surgical reconstruction company leading the development and commercialization of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that the company will participate in the Canaccord Genuity Medical Technologies & Diagnostics Forum to be held Thursday, November 17, 2016 in New York City.
Antony Koblish, president and CEO of TELA Bio, will present an overview of the company's OviTex™ portfolio of products for use in ventral hernia repair and abdominal wall reconstruction.
For more information and to register for the webcast, visit http://wsw.com/webcast/canaccord24/tela. The webcast will be archived for 90 days following the presentation.
About TELA Bio, Inc.
TELA Bio, Inc. is a privately owned company focused on bringing innovative, cost-effective, surgical reconstruction solutions to surgeons, hospitals and patients. The company's OviTex™ Reinforced BioScaffolds (RBSs) products, designed for hernia repair and abdominal wall reconstruction procedures, integrate polymer and biologic materials through engineering design principles. The OviTex portfolio is supported by high-quality, data-driven science and extensive pre-clinical research that has consistently demonstrated the advantages of an RBS over commercially available materials for certain patients and procedures. OviTex is commercially available in the U.S., and TELA Bio plans to launch OviTex in the European Union. The company is collaborating with leading surgeons to drive rapid product development and establish TELA Bio as a leader in surgical reconstruction. To learn more about TELA Bio visit http://www.telabio.com.
Adam Daley Berry & Company Public Relations212email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tela-bio-to-participate-in-canaccord-genuity-medical-technologies-and-diagnostics-forum-300359215.html
SOURCE TELA Bio, Inc.